C.R. Bard closes $200 M acquisition of SenoRx

Tue, 07/06/2010 - 8:45am
The Associated Press

C.R. Bard has closed on its acquisition of SenoRx, the medical device maker said Tuesday.

SenoRx makes devices used in detecting and treating breast cancer and in May, Bard announced it would buy the company for about $200 million.

SenoRx's products include the EnCor breast biopsy system, Gel Mark breast tissue markers, and Contura balloon catheter. Its revenue totaled $55.6 million in 2009.

The acquisition of SenoRx, based in Irvine, Calif., will reduce Bard's 2010 net income by 8 to 11 cents per share.

Bard said SenoRx Inc. is now part of its peripheral vascular unit.

Shares of C.R. Bard Inc. rose 98 cents to $77.46 Tuesday.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.